Evidence map›Paper›PMID 35199053›Full record

ArticleJTO clinical and research reports2022

Roberta Minari, Samuel Valentini, Denise Madeddu, Andrea Cavazzoni, Silvia La Monica, Costanza Anna Maria Lagrasta, Roberto Bertorelli, Veronica De Sanctis, Paola Fassan, Cinzia Azzoni and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Roberta MinariMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Samuel ValentiniDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Denise MadedduDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Andrea CavazzoniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Silvia La MonicaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Costanza Anna Maria LagrastaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Roberto BertorelliNGS Core Facility, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Veronica De SanctisNGS Core Facility, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Paola FassanNGS Core Facility, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Cinzia AzzoniUnit of Pathological Anatomy, University Hospital of Parma, Parma, Italy.
Lorena BottarelliUnit of Pathological Anatomy, University Hospital of Parma, Parma, Italy.
Caterina FratiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Letizia GnettiUnit of Pathological Anatomy, University Hospital of Parma, Parma, Italy.
Francesco FacchinettiInstitut National de la Santé et de la Recherche Médicale (INSERM) U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.
Pier Giorgio PetroniniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Roberta AlfieriDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Alessandro RomanelDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Marcello TiseoMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
University of Parma · ITUniversity of Trento · ITUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs. Here, we report a case of a patient with metastatic ALK-positive lung adenocarcinoma with an impressive resistance to sequential treatment with ALK TKIs mediated by

methodsThe patient received, after chemotherapy and 7 months of crizotinib, brigatinib and lorlatinib with no clinical benefit to both treatments. A study of resistance mechanisms was performed with whole exome sequencing on different biological samples; primary cell lines were established from pleural effusion after lorlatinib progression.

resultsAt whole exome sequencing analysis,

conclusionsIn conclusion,

Indexed as

ALK TKIsMYC amplificationNSCLCResistance mechanismYES1 amplification

Identifiers

PMID35199053
PMCPMC8851257
OpenAlexW4206797531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.